These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3741741)

  • 1. Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa.
    Bassi S; Albizzati MG; Calloni E; Sbacchi M; Frattola L
    Br J Clin Pract; 1986 Jul; 40(7):273-5. PubMed ID: 3741741
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined treatment in Parkinson's disease.
    Wheatley D
    Practitioner; 1983 Mar; 227(1377):446-7. PubMed ID: 6889232
    [No Abstract]   [Full Text] [Related]  

  • 3. L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
    Ambrozi L; Birkmayer W; Riederer P; Youdim MB
    Br J Pharmacol; 1976 Nov; 58(3):423P-424P. PubMed ID: 791430
    [No Abstract]   [Full Text] [Related]  

  • 4. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 7. Mental impairment in Parkinson's disease. The role of anticholinergic drugs.
    Meco G; Casacchia M; Lazzari R; Franzese A; Castellana F; Carta A; Iannuccelli M; Agnoli A
    Acta Psychiatr Belg; 1984; 84(4):325-35. PubMed ID: 6507124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
    van der Drift JH
    Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modification of disturbed visual-spatial performance in patients with Parkinson's disease by treatment with L-dopa].
    Jacobi P; Schneider E; Gundelsheimer W; Fischer PA
    Nervenarzt; 1974 Nov; 45(11):588-94. PubMed ID: 4453348
    [No Abstract]   [Full Text] [Related]  

  • 15. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 16. Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease.
    Mastrosimone F; Colucci d'Amato C; De Angelis G; Iaccarino C; Giordano L; Marmo E
    J Med; 1980; 11(5-6):377-83. PubMed ID: 6962824
    [No Abstract]   [Full Text] [Related]  

  • 17. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapeutic effect of disipal in Parkinson's disease].
    Zheng JH
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):199-200. PubMed ID: 4075907
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.